Agilent Technologies Introduces SureSelect Human All-Exon UTRs for Next-Generation Sequencing


WEBWIRE – Thursday, November 08, 2012

Products Provide Exceptional Efficiency; Exome Samples Ready for Sequencing the Next Day

SANTA CLARA, Calif.

Agilent Technologies Inc. (NYSE: A) today introduced SureSelect Human All-Exon V5 and V5 + UTRs for next-generation sequencing. The new all-exon solutions incorporate the latest advances from Agilent Genomics, the originator of target enrichment for human exomes.

SureSelect Human All-Exon V5 continues to build on the market-leading SureSelect Target Enrichment platform, enabling faster turnaround-producing exome samples ready for sequencing the next day. It also provides even greater sequencing efficiencies as well as comprehensive coverage of the most current genomics databases, including RefSeq, CCDS, GENCODE, miRBase, TCGA and UCSC.

Optimized to provide maximum specificity and sensitivity, these new all-exon solutions require only 4 Gb of total sequencing, which represents up to 60 percent less sequencing compared with competitive human exome offerings.

“We are excited to continue delivering high-performance exome target capture products,” said Kathleen Shelton, Agilent’s senior marketing director for genomics. “Our V5 and V5+ UTRs are the most up-to-date and comprehensive exome kits available. Together with a streamlined workflow, they enable greater sample throughput with significantly less sequencing-which means researchers can spend less time and expense on sequencing, and more time on discovery.”

The SureSelect Human All-Exon V5 is part of the SureSelect portfolio and available as a complete SureSelectXT or SureSelectXT2 solution. It is also well matched with SureSelect Custom and HaloPlex Target Enrichment Systems, which are ideal for follow-up studies.

Additionally, Agilent provides complete next-generation workflow solutions, including QC, automation, PCR, and analysis. For more information, visit www.genomics.agilent.com/CollectionSubpage.aspx?PageType=Product&SubPageType=ProductDetail&PageID=3041

About Agilent in Genomics

Agilent Technologies Inc. is a global leader in target enrichment for next-generation sequencing and genomic microarrays. The Agilent SureSelect and HaloPlex Target Enrichment Systems enable researchers to easily choose which segments of a genome to sequence, avoiding the time and expense needed to sequence the entire genome. HaloPlex and its same-day sample-to-sequencer workflow is well suited for next-generation desktop sequencers, whereas SureSelect’s ability to accurately capture whole exomes and whole methylomes in a single reaction pairs well with high-throughput next-generation sequencing systems. These are just two products arising from Agilent’s expertise in synthesizing custom complex mixtures of long oligonucleotide gained in microarray manufacturing. Additional product lines built on this core technology include microarrays for genome-wide measurement of gene expression and for comparative genomics hybridization, as well as SureFISH, a highly specific and sensitive oligonucleotide fluorescent in situ hybridization product line. In addition to oligonucleotide-based products, Agilent offers a microfluidic bioanalyzer to measure sample quality, a target enrichment tool to speed next-generation sequencing, and a full set of reagents, hardware, methods and bioinformatics software for genomic experiments.
About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,000 employees serve customers in more than 100 countries. Agilent had net revenues of $6.6 billion in fiscal 2011. Information about Agilent is available at www.agilent.com.



WebWireID164477





This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.